Geron Corporation (GERN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $622.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Geron Corporation (GERN) Competitors
The companies most similar to Geron are Prothena Corporation (PRTA), Neurogene (NGNE) and Gyre Therapeutics (GYRE). By market cap, Geron ranks 6th of the 13 companies on this page; Corvus Pharmaceuticals (CRVS) is the largest at $897.52M.
Peer Comparison
GERN's ROIC of -7.4% is above the peer median of -14.9%, and its revenue growth of 27.4% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Geron (GERN) | $622.98M | N/A | 2.9x | -22.0% | -7.4% | 27.4% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Entera Bio Ltd (ENTX) | $541.57M | N/A | N/A | 0.0% | -8.5% | -100.0% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| Ginkgo Bioworks Holdings (DNA) | $622.97M | N/A | 6.1x | -192.0% | N/A | -5.7% | 0.00% |
| Kura Oncology Inc (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Peer median | $582.27M | 14.2x | 5.0x | 0.0% | -14.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Geron, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Entera Bio Ltd (ENTX) | Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies... | ENTX competitors |
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| Ginkgo Bioworks Holdings (DNA) | Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms... | DNA competitors |
| Kura Oncology Inc (KURA) | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. | KURA competitors |
Frequently Asked Questions About GERN
Who are Geron's main competitors?
The companies most similar to Geron include Prothena Corporation (PRTA), Neurogene (NGNE), Gyre Therapeutics (GYRE), PepGen (PEPG) and Corvus Pharmaceuticals (CRVS), listed from the closest match.
Who is Geron's biggest competitor?
Corvus Pharmaceuticals (CRVS) is the largest of the similar companies at $897.52M; Prothena Corporation (PRTA) is the closest match by business profile, size, sector and industry.
How does GERN stock compare with its competitors?
GERN's P/S is 2.9x against a peer median of 5.0x; its net margin is -22.0% against a peer median of 0.0%.
Which of Geron's competitors pays a higher dividend?
Geron pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Geron bigger than its competitors?
No. Geron is 6th by market cap among the 13 companies on this page; the largest is Corvus Pharmaceuticals (CRVS) at $897.52M.
GERN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors